After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...
The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster ...
The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug ...
The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...
The denial sets back a drug Scholar Rock hopes to become part of a new standard of care for spinal muscular atrophy, treatment for which has changed dramatically over the last decade.
After an earlier rejection that drew criticism from some observers, the FDA quickly accepted Stealth BioTherapeutics’ new ...
The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures ...
Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular ...
Unified data also improves AI outputs. For example, by drawing up-to-date information from a variety of an organization’s ...
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...
The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback